--- title: "Inmune Bio | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285613335.md" datetime: "2026-05-07T20:31:56.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285613335.md) - [en](https://longbridge.com/en/news/285613335.md) - [zh-HK](https://longbridge.com/zh-HK/news/285613335.md) --- # Inmune Bio | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.2. INmune Bio Inc. operates as one reportable segment, and its financial results are presented on a consolidated basis . #### Segment Revenue For the three months ended March 31, 2026, INmune Bio Inc. reported no revenue, compared to $50 thousand for the same period in 2025 . #### Net Loss INmune Bio Inc. reported a net loss of - $5.4 million for the three months ended March 31, 2026, an improvement from a net loss of - $9.7 million for the three months ended March 31, 2025 . #### Total Operating Expenses Total operating expenses decreased to $5.812 million for the three months ended March 31, 2026, from $9.955 million for the same period in 2025 . #### Research and Development Expenses Research and development expenses were $3.641 million for the three months ended March 31, 2026, a decrease from $7.639 million for the same period in 2025 . This $3.998 million decrease was primarily due to a $4.5 million reduction in expenses related to the Alzheimer’s clinical program, which completed its Phase 2 trial in 2025, and $0.5 million lower compensation expense . These reductions were partially offset by $1.0 million higher CORDStrom/INKmune costs related to preparations for marketing authorization submissions . #### General and Administrative Expenses General and administrative expenses decreased to $2.171 million for the three months ended March 31, 2026, from $2.316 million for the same period in 2025, mainly due to lower stock-based compensation expense . #### Loss from Operations Loss from operations was - $5.812 million for the three months ended March 31, 2026, compared to - $9.905 million for the same period in 2025 . #### Other Income, Net Other income, net, increased to $0.4 million for the three months ended March 31, 2026, from $0.2 million for the same period in 2025, primarily due to a gain on the settlement of a vendor payable . #### Cash Flow from Operating Activities Net cash used in operating activities was - $3.4 million for the three months ended March 31, 2026, an improvement from - $6.8 million for the same period in 2025 . This was mainly due to a lower net loss and a decrease in research and development tax credit receivable of $3.8 million, partially offset by a decrease in accounts payable and accrued liabilities of $3.0 million . #### Cash and Cash Equivalents Cash and cash equivalents totaled $21.358 million as of March 31, 2026, down from $24.751 million as of December 31, 2025 . #### Unique Metrics Stock-based compensation expense was $1.5 million for the three months ended March 31, 2026, compared to $2.1 million for the same period in 2025 . As of March 31, 2026, there was approximately $8.4 million of total unrecognized compensation cost related to non-vested stock options, expected to be recognized over a weighted-average period of 2.27 years . The research and development tax credit receivable was $479 thousand as of March 31, 2026, for R&D expenses in Australia, and $0 for the UK . A $25 thousand milestone payable to Immune Ventures, a related party, was recorded as of March 31, 2026, and December 31, 2025 . #### Future Outlook and Strategy INmune Bio Inc. plans to file a Marketing Authorization Application (MAA) in the UK and EU, followed by a Biologics License Application (BLA) with the U.S. FDA for CORDStrom, targeted for 2026 . For XPro1595, the company intends to pursue strategic partnership opportunities for further development rather than independent advancement into later stages . INmune Bio Inc. expects to continue incurring significant losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern, and is evaluating various financing strategies to secure additional capital . ### Related Stocks - [INMB.US](https://longbridge.com/en/quote/INMB.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [INM Stock Alert: What to Know as InMed, Mentari Announce Merger](https://longbridge.com/en/news/287099341.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md)